MNOV

+ Watchlist + Portfolio

MediciNova, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.38
52-Week Range: $1.17 – $1.96
Market Cap: $67.43M
P/E (TTM): —
EPS (TTM): -0.21
Dividend Yield: —

Advanced Metrics

Price/Book: 1.81
PEG Ratio: —
Return on Equity: -25.56%
Return on Assets: -16.41%
Gross Margin: 37.75%
Operating Margin: -554.31%
Profit Margin: 0.00%
Current Ratio: 8.75
Debt/Equity: 0.00
Total Debt: $117.04K
Free Cash Flow: $-5.74M
Revenue Growth: 240.60%
Earnings Growth: —
Enterprise Value: $42.13M

MNOV Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$1.00M	$0.00	$409.66K
Cost of Revenue	—	—	$0.00	$378.61K
Gross Profit	—	—	$0.00	$31.05K
Research & Development	$9.14M	$5.66M	$7.19M	$7.15M
Selling, General & Admin	$5.48M	$5.24M	$5.48M	$6.16M
Operating Expenses	$14.63M	$10.90M	$12.68M	$13.31M
Operating Income	-$14.63M	-$9.90M	-$12.68M	-$13.28M
EBITDA	-$14.61M	-$9.88M	-$12.65M	-$13.26M
Pretax Income	-$14.07M	-$8.57M	-$11.04M	-$11.99M
Income Tax	$2.82K	$3.05K	$5.54K	$5.99K
Net Income	-$14.07M	-$8.57M	-$11.05M	-$12.00M
Diluted EPS	-0.29	-0.17	-0.23	-0.24
Diluted Shares	49.05M	49.05M	49.05M	49.06M

MNOV Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$18.51M	$51.00M	$40.36M	$30.81M
Current Assets	$58.99M	$51.17M	$41.07M	$30.99M
Total Assets	$74.15M	$66.27M	$55.88M	$45.60M
Current Liabilities	$3.19M	$3.28M	$2.96M	$3.80M
Total Debt	$157.50K	$215.93K	$193.77K	$194.33K
Total Liabilities	$3.91M	$3.89M	$3.37M	$4.02M
Retained Earnings	-$407.13M	-$415.70M	-$426.75M	-$438.75M
Shareholders' Equity	$70.24M	$62.38M	$52.50M	$41.59M
Working Capital	$55.80M	$47.90M	$38.12M	$27.19M

MNOV Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$12.91M	-$7.43M	-$10.64M	-$9.81M
Capital Expenditure	-$5.01K	-$21.30K	-$895.00	-$2.90K
Free Cash Flow	-$12.92M	-$7.45M	-$10.64M	-$9.81M
Depreciation & Amortisation	$17.71K	$20.30K	$21.08K	$20.10K
Stock-Based Compensation	$642.52K	$710.71K	$1.19M	$829.10K
Investing Cash Flow	-$40.01M	$39.91M	-$697.00	-$2.90K
Financing Cash Flow	$7.92K	$0.00	$0.00	$244.02K
Net Change in Cash	-$52.91M	$32.48M	-$10.64M	-$9.57M

MNOV Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$134.60K	$123.32K	$151.74K	$186.98K
Cost of Revenue	$0.00	$116.35K	$115.27K	$146.99K	$170.10K
Gross Profit	$0.00	$18.25K	$8.05K	$4.75K	$16.88K
Research & Development	$1.84M	$2.19M	$1.58M	$1.54M	$1.26M
Selling, General & Admin	$1.36M	$1.44M	$1.81M	$1.55M	$1.59M
Operating Expenses	$3.20M	$3.63M	$3.39M	$3.10M	$2.85M
Operating Income	-$3.20M	-$3.61M	-$3.38M	-$3.09M	-$2.84M
EBITDA	-$3.20M	-$3.60M	-$3.38M	-$3.09M	-$2.83M
Pretax Income	-$2.86M	-$3.28M	-$3.05M	-$2.80M	-$2.59M
Net Income	-$2.86M	-$3.28M	-$3.05M	-$2.80M	-$2.59M
Diluted EPS	-0.06	-0.07	-0.06	—	-0.05
Diluted Shares	49.05M	49.05M	49.05M	—	49.22M

MNOV Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$36.57M	$34.26M	$32.56M	$30.81M	$27.33M
Receivables	—	$134.60K	—	—	$245.10K
Current Assets	$37.68M	$35.12M	$32.92M	$30.99M	$28.15M
Total Assets	$52.43M	$49.82M	$47.58M	$45.60M	$42.70M
Current Liabilities	$2.13M	$2.65M	$3.34M	$3.80M	$3.10M
Total Debt	$189.86K	$301.88K	$180.75K	$194.33K	$165.20K
Total Liabilities	$2.50M	$2.97M	$3.61M	$4.02M	$3.30M
Retained Earnings	-$429.62M	-$432.90M	-$435.95M	-$438.75M	-$441.34M
Shareholders' Equity	$49.93M	$46.86M	$43.96M	$41.59M	$39.41M
Working Capital	$35.55M	$32.48M	$29.59M	$27.19M	$25.05M

MNOV Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$3.78M	-$2.31M	-$1.70M	-$2.02M	-$3.47M
Capital Expenditure	—	—	—	—	-$10.82K
Free Cash Flow	-$3.78M	-$2.31M	-$1.71M	-$2.02M	-$3.48M
Depreciation & Amortisation	$5.18K	$5.06K	$5.30K	$4.55K	$4.26K
Stock-Based Compensation	$285.94K	$204.90K	$157.69K	$180.56K	$407.76K
Investing Cash Flow	$0.00	$0.00	-$2.90K	$0.00	-$10.82K
Net Change in Cash	-$3.78M	-$2.31M	-$1.71M	-$1.77M	-$3.48M

Market Snapshot

About

MediciNova is a clinical-stage biopharmaceutical company developing therapies for diseases with unmet medical needs. The company focuses on MN-166 for neurological disorders and MN-001 for fibrotic and metabolic diseases.